What retatrutide is, and what it is not

A triple agonist still in development

Retatrutide is an investigational weekly injection designed to activate three metabolic hormone receptors at once: GIP, GLP-1, and glucagon. Writers sometimes call it a triple-G or triple-agonist medicine. That nickname is marketing shorthand, not an FDA-approved brand, and it is not a reason to treat gray-market vials as equivalent to a licensed drug.

This page is educational, not medical advice. Beema Health does not currently offer retatrutide, does not compound it, and does not run a public waitlist for it. If you are looking for care that exists today, a licensed provider may consider other GLP-1-class prescription options after reviewing your history. Compounded semaglutide is not FDA-approved and is considered only when legally available and clinically appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate.

Interest in retatrutide is high because Phase 2 obesity data showed large average weight reductions, and because 2026 Phase 3 TRIUMPH readouts kept that story in the news. Large trial means are still averages. They do not tell you what will happen to one person, and they do not make an unapproved product safe to order from a website.

How the three-receptor design is supposed to work

GLP-1 receptor agonists reduce appetite and slow gastric emptying. That is the pathway behind several FDA-approved medicines used in type 2 diabetes and chronic weight management. GIP receptor activity is the second incretin pathway used by tirzepatide. Glucagon receptor activity is the third piece in retatrutide's design. In theory, glucagon signaling can increase energy expenditure and affect liver fat handling, which is why researchers study this combination for obesity and related metabolic disease.

Theory is not a substitute for a completed FDA review. Combining three pathways can also change the side-effect profile. Gastrointestinal effects remain common in this class. Phase 2 work also described dose-related heart-rate increases that peaked around 24 weeks and later declined. Those signals are exactly the kind of finding a regulator wants to see tracked in large, longer trials before a product is marketed.

• GLP-1 activity: appetite and stomach-emptying effects familiar from approved GLP-1 medicines
• GIP activity: second incretin pathway, also used by tirzepatide
• Glucagon activity: the extra receptor that makes retatrutide a triple agonist, still under study

What published and company-reported trials show

The most carefully published obesity dataset remains the Phase 2 trial by Jastreboff and colleagues in the New England Journal of Medicine. Adults with obesity, or overweight plus a weight-related condition, received weekly retatrutide or placebo for 48 weeks. At the 12 mg dose, mean body-weight change was about 24.2%, compared with about 2.1% with placebo. Gastrointestinal events were the most common adverse effects and were partly mitigated by a lower starting dose.

Phase 3 is the TRIUMPH program. Lilly has described studies in obesity with and without type 2 diabetes, in severe obesity with cardiovascular disease, and in other complications such as knee osteoarthritis pain. On July 23, 2026, the company said TRIUMPH-2 and TRIUMPH-3 met their primary endpoints. In TRIUMPH-3, the 12 mg dose was associated with 22.6% mean weight loss at 80 weeks, versus 3.2% with placebo; the 9 mg dose was associated with 21.6%. Detailed peer-reviewed papers for those 2026 topline figures were still pending at the time Lilly issued the release.

Lilly also said it is completing the manufacturing package needed for a Biologics License Application and plans to submit to the FDA in the first quarter of 2027. That timeline can move. Submission is not approval. Until FDA action, retatrutide is not a medicine a U.S. clinic can routinely prescribe.

Safety, access, and unregulated products

Incretin medicines as a class are associated with nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose increases. Retatrutide trials have shown a similar gastrointestinal pattern. Phase 2 also flagged heart-rate changes. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are generally excluded from GLP-1-class obesity medicines that carry a boxed warning based on rodent C-cell findings. Whether retatrutide would carry the same labeled warnings is a question for a future FDA label, not for a blog.

Lilly's own explainer is blunt: retatrutide has not been approved by any regulator and is legally available only through company trials. Products sold as research peptides, compounded retatrutide, or gray-market injections are not a substitute for that process. They may be mislabeled, contaminated, or dosed incorrectly. Wanting the next molecule is understandable. Ordering an unverified vial is not a clinical plan.

What Beema Health offers instead, today

Beema Health is a cash-pay telehealth program for medical weight loss. Adults in all 50 U.S. states can complete an online intake. A licensed provider reviews history, medications, and BMI-related factors and decides whether compounded semaglutide, compounded tirzepatide, or no medication is appropriate. Prescribing is never guaranteed. Medication availability can still vary by state compounding rules and pharmacy fulfillment.

If you are comparing headlines about retatrutide with care you can actually start, read the educational overview of GLP-1 medicines for weight loss, then the live program pages for compounded semaglutide and compounded tirzepatide. Those pages list current cash-pay rates. They are not a promise that any pipeline drug will arrive next month.

Questions worth taking to a licensed provider

If retatrutide news is what brought you here, a useful clinic visit still starts with your history, not with a press release. Ask whether an available GLP-1-class option fits your conditions and other medicines. Ask how side effects would be monitored. Ask what happens if you stop treatment, because weight regain after withdrawal is well documented for this class in general. Do not skip those questions while waiting for a 2027 filing window.

Clinical-trial participation, when you qualify, is the only lawful way to receive investigational retatrutide. Listing sites such as ClinicalTrials.gov are the right place to look, not social-media vendors. Beema Health cannot enroll you in Lilly's TRIUMPH program and should not be asked to source the molecule.

Frequently asked questions

Sources

1. [1] Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.
2. [2] Eli Lilly. What to know about retatrutide (investigational status and TRIUMPH program overview).
3. [3] Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). PR Newswire. July 23, 2026.
4. [4] U.S. Food and Drug Administration. Medicines in development are not approved products; FDA reviews complete applications after submission.